Information Provided By:
Fly News Breaks for June 30, 2016
TSRO
Jun 30, 2016 | 07:43 EDT
SunTrust raised its price target on TESARO after the company announced positive data for its niraparib drug in ovarian cancer. The firm is encouraged by what it sees as "the significant increase" in progression free survival that the patients who took the drug exhibited. SunTrust adds that the progression free survival rate came in above the levels seen among patients who took competing drugs. It reiterates a Buy rating on TESARO.
News For TSRO From the Last 2 Days
There are no results for your query TSRO
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.